News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Pomerantz LLP is investigating Criteo S.A. for potential securities fraud following the company's August 5, 2026 earnings report, which revealed an 11% year-over-year revenue decline and a 49% drop in net income. The announcement also included a CFO change, triggering a 23.88% stock price decline to $17.05.
Johnson & Johnson stock declined 2.22% on September 8, 2026, underperforming the S&P 500's 0.58% loss. The company is expected to report earnings on October 13, 2026, with forecasted EPS of $2.95 (up 5.36% YoY) and revenue of $25.36 billion (up 5.71% YoY). JNJ holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 23.75, trading at a premium to its industry average.
California Water Service launched its 13th annual Tap Into Learning program for the 2026-27 school year, offering water conservation education to K-12 students across its service areas. The program includes field trips, art competitions, grants for classroom projects, and conservation pledges. In the previous year, the program received 138 entries and awarded 12 field trip experiences, 10 art prizes, and 10 grants.
Filed: 2026-09-09 AccNo: 0001451809-26-000068 Size: 856 KB Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-09 AccNo: 0001193125-26-385477 Size: 18 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Entegris (NASDAQ:ENTG) has outperformed the market over the past 10 years by 10.49% on an annualized basis producing an average annual return of 24.13%. Currently, Entegris has a market capitalization of $21.58 billion.
Filed: 2026-09-09 AccNo: 0000109380-26-000117 Size: 203 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Tapestry (NYSE:TPR) has outperformed the market over the past 5 years by 12.48% on an annualized basis producing an average annual return of 23.88%. Currently, Tapestry has a market capitalization of $23.69 billion.
Filed: 2026-09-09 AccNo: 0001104659-26-105989 Size: 195 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
SpaceX shares stay above the IPO price through two insider unlocks, but Wednesday’s larger 700 million-share release may test investor demand.
WESCO International (NYSE:WCC) has outperformed the market over the past 5 years by 14.72% on an annualized basis producing an average annual return of 26.11%. Currently, WESCO International has a market capitalization
Filed: 2026-09-09 AccNo: 0001185185-26-003879 Size: 451 KB Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
InnovAge Holding (NASDAQ:INNV) reported fourth-quarter financial results on Tuesday. The transcript from the company's fourth-quarter earnings call has been provided below. This transcript is brought to you by
Filed: 2026-09-09 AccNo: 0001279569-26-000862 Size: 220 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
ServiceTitan (NASDAQ:TTAN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Trump's approval rating falls in a new poll, with the Iran War a big factor.
Aramark (NYSE:ARMK) has outperformed the market over the past 5 years by 7.82% on an annualized basis producing an average annual return of 19.21%. Currently, Aramark has a market capitalization of $15.18 billion.
Filed: 2026-09-09 AccNo: 0001104659-26-105984 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Zacks highlights two Strong Buy stocks: Bloom Energy (BE), a renewable energy company with improved earnings outlook and strong technical momentum, and Abercrombie & Fitch (ANF), a specialty retailer benefiting from sales growth, inventory management, and raised fiscal 2026 guidance.
CrowdStrike and OKTA both show strong quarter-over-quarter revenue growth driven by increased AI-related cybersecurity demand. CrowdStrike's revenue nearly doubled over eight quarters ($1.0B to $1.5B), significantly outpacing OKTA's steady growth ($665M to $805M). However, OKTA is profitable with a 13% operating margin, while CrowdStrike remains unprofitable at -2%. CrowdStrike commands a premium valuation (P/S ratio of 38) versus OKTA's more reasonable multiple (P/S of 10), making OKTA potentially better value for investors despite CrowdStrike's faster growth trajectory.
Pomerantz LLP is investigating potential securities fraud claims against Wolfspeed, Inc. following the company's disappointing Q4 2026 earnings report on August 19, 2026. Wolfspeed reported revenue of $149.6 million, significantly missing the consensus estimate of $223.55 million, and posted an adjusted loss of $2.26 per share versus the expected $0.52 per share. The stock declined 9.42% to $26.35 per share on August 20, 2026.
Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.
Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.
Pomerantz LLP is investigating potential securities fraud claims against Emergent BioSolutions following the company's August 5, 2026 earnings report. Emergent reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a $180.2 million net loss, and cut full-year revenue guidance by 10.8%. The company attributed the decline to increased competitive intensity. Emergent's stock price fell 29.58% to $5.31 per share on August 6, 2026.
Rosen Law Firm is encouraging investors who suffered losses in Cogent Communications Holdings, Inc. (CCOI), UWM Holdings Corporation (UWMC), and UP Fintech Holding Limited (TIGR) to join securities class action lawsuits. The firm alleges that Cogent made false statements about its optical wavelength backlog and financial capacity, while investigations are ongoing for the other companies. The lead plaintiff deadline for the Cogent case is September 21, 2026.
Pomerantz Law Firm has filed a class action lawsuit against Alibaba Group Holding Limited, alleging securities fraud and unlawful business practices. The lawsuit follows two major negative events: Alibaba's inclusion on the U.S. Department of Defense's list of Chinese military companies (causing a 39% stock price drop on June 10, 2026), and accusations from Anthropic that Alibaba used fraudulent accounts to gain unauthorized access to its Claude AI model (causing a 7.34% price decline on June 25, 2026). Investors have until October 5, 2026, to request Lead Plaintiff status.
Seres Therapeutics granted stock options to purchase 4,200 shares to two new employees on September 4, 2026, with an exercise price of $5.72 per share under its 2022 Employment Inducement Award Plan. The options vest 25% on the first anniversary and 6.25% quarterly thereafter.
Pomerantz Law Firm is investigating L3Harris Technologies for potential securities fraud following the immediate resignation of Chairman and CEO Christopher Kubasik on August 17, 2026, due to conduct inconsistent with company values. The announcement triggered a 4.61% stock price decline, falling $13.44 per share to $278.38.
CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.